- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02955888
Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
A Phase 2, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and Its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a Phase 2, multi-center, double blind, placebo controlled study to evaluate the safety and tolerability of PBI-4050, and its effects on the pancreatic, pulmonary functions and on various biomarkers in Cystic Fibrosis patients with abnormal glucose tolerance. Patients with abnormal glucose tolerance have elevated glucose level either at 1 hour or 2 hour during an Oral Glucose Tolerance Test (OGTT).
A total of 90 patients will be enrolled for study participation. A Data Safety Monitoring Board (DSMB) will continually review individual patients safety data obtained from the 90 patients. When the first 15 patients have completed at least 1 month of study treatment, the DSMB will meet formally to determine whether additional patients may be enrolled, the study should continue with changes or if the study should be stopped. In addition, the DSMB will review the PK data and may recommend dose adjustment based on the PK results.
The total duration of study participation for each patient is at least 32 weeks, including up to 4 weeks of a screening period, 24 weeks of study treatment and 4 weeks of safety follow-up.
Patients who choose to participate in the open label extension will be in the study for an additional 24 weeks of study treatment and 4 weeks of safety follow-up (for a total of 56 weeks).
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Quebec, Canadá
- Institut Universitaire de Cardiologie et de Pneumologie de l'Université Laval (IUCPQ)
-
-
British Columbia
-
Vancouver, British Columbia, Canadá
- St. Paul's Hospital - Pacific Lung Health Centre (PLHC)
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá
- Queen Elizabeth II Health Science Center
-
-
Ontario
-
Ottawa, Ontario, Canadá
- Ottawa Hospital Research Institute
-
Toronto, Ontario, Canadá
- St. Michael's Hospital
-
-
Quebec
-
Montreal, Quebec, Canadá
- Institut de recherches cliniques de Montréal (IRCM)
-
Sherbrooke, Quebec, Canadá
- Centre de recherche du Centre hospitalier Universitaire de Sherbrooke
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patient is 18 years of age or older at screening.
- Patient has a documented and confirmed CF diagnosis.
- Patient has performed an OGTT for diagnosis of INDENT, IGT and de novo CFRD within 12 months prior to screening visit.
- Patient has a Body Mass Index (BMI) of at least 17 kg/m2.
- Patient has signed written informed consent.
- Patient is able and willing to self-monitor blood glucose level at home.
- Female patients of childbearing potential must have a negative pregnancy test (serum or urine) and agree to use adequate birth control from screening throughout the study and for the 30 days after the last study drug administration.
- If a male patient has not been vasectomized at least 6 months before screening and partners with a woman of childbearing potential, he must be willing to use an acceptable contraceptive method throughout the study and for the 30 days after the last study drug administration.
Exclusion Criteria:
- Patient has recent or ongoing infection requiring intravenous treatment with an anti-infective agent within 30 days before screening.
- Patient is concurrently taking high dose of ibuprofen (>30 mg/kg) or is using corticosteroids (except inhaled and topical corticosteroids).
- Patient is currently using weight-loss medications.
- 4. Patient has used any moderate/potent inhibitor of cytochrome P450 (CYP) 2C9 isozyme or strong inhibitor of CYP3A isozyme within 30 days prior to the first study drug administration.
- Patient has significantly elevated liver enzyme levels, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 Upper Limit of Normal (ULN) or total bilirubin above ULN at screening.
- Patient has a history of chronic alcohol or other substance abuse as determined at screening that may prevent study compliance based on Investigator judgment.
- History of malignancy of any organ system, treated or untreated, within the past 5 years other than basal or squamous cell skin cancer.
- Patient has unstable chronic heart failure that has required change in therapy within 2 months prior to screening.
- Patient with known non-controlled history of infection with Human Immunodeficiency Virus (HIV) and/or active Hepatitis.
- Woman who is pregnant, breast-feeding or planning a pregnancy during the course of the study.
- Woman of childbearing potential who is unwilling to use adequate birth control throughout the duration of the study.
- Patient has any condition that, in the Investigator's opinion, is likely to interfere with study conduct and compliance.
- Patient has participated in an investigational clinical trial within 30 days (or 5 half-lives, whichever is longer) prior to screening visit.
- Patient is under insulin and/or repaglinide treatment at screening/baseline
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: PBI4050
Cuatro cápsulas de 200 mg (total 800 mg) administradas por vía oral, una vez al día.
|
Investigational Medicinal Product
|
Comparador de placebos: Placebo
Four 200 mg capsules (total 800 mg) administered orally, once daily.
|
Comparador
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Subjects with Adverse Events (Combined Main Study and Extension Study Participation)
Periodo de tiempo: Baseline to 1 Year
|
Adverse Event data (including abnormal laboratory values) collected up to final follow-up (30 days after last dose of study drug).
Serious Adverse Events that were ongoing at the follow-up visit will be followed until the event resolved, returned to baseline, or was determined to be a stable or chronic condition.
|
Baseline to 1 Year
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Change from Baseline in glucose level following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation)
Periodo de tiempo: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline of insulin-secretion following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation)
Periodo de tiempo: Up 1 Year
|
Up 1 Year
|
Change from Baseline of HbA1C following Oral Glucose Tolerance Test (OGTT) (Combined Main Study and Extension Study Participation)
Periodo de tiempo: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline in pulmonary function parameters (FEV1 ) (Combined Main Study and Extension Study Participation)
Periodo de tiempo: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline in pulmonary function parameters ( FVC) (Combined Main Study and Extension Study Participation)
Periodo de tiempo: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline in pulmonary function parameters (FEV1/FVC ratio) (Combined Main Study and Extension Study Participation)
Periodo de tiempo: Up to 1 Year
|
Up to 1 Year
|
Change from Baseline in pulmonary function parameters (Forced Expiratory Flow (FEF25%-75%)) (Combined Main Study and Extension Study Participation)
Periodo de tiempo: Up to 1 Year
|
Up to 1 Year
|
Change from baseline in weight (Combined Main Study and Extension Study Participation)
Periodo de tiempo: Up to1 Year
|
Up to1 Year
|
Otras medidas de resultado
Medida de resultado |
Periodo de tiempo |
---|---|
Changes from baseline in fibrotic and inflammatory biomarkers in blood (Combined Main Study and Extension Study Participation)
Periodo de tiempo: Up to 1 Year
|
Up to 1 Year
|
Changes from baseline in fibrotic and inflammatory biomarkers in urine (Combined Main Study and Extension Study Participation)
Periodo de tiempo: Up to1 Year
|
Up to1 Year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: John Moran, MD, Liminal BioSciences Ltd.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PBI-4050-CT-9-07
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Fibrosis quística
-
Peking Union Medical College HospitalReclutamientoFibrosis Retroperitoneal IdiopáticaPorcelana
-
Peking Union Medical College HospitalReclutamiento
-
Peking Union Medical College HospitalReclutamientoFibrosis Retroperitoneal IdiopáticaPorcelana
-
San Gerardo HospitalTerminadoFibrosis pulmonar idiopática | Fibrosis cardiaca | Fibrosis ArterialItalia
-
Assistance Publique - Hôpitaux de ParisReclutamientoFibrosis Retroperitoneal IdiopáticaFrancia
-
Peking Union Medical College HospitalReclutamientoFibrosis Retroperitoneal IdiopáticaPorcelana
-
Hospital de Clinicas de Porto AlegreDesconocidoFibrosis quística | Exacerbación pulmonar de fibrosis quística | Fibrosis quística en niños | Fibrosis quística con exacerbaciónBrasil
-
University of ParmaDesconocidoFibrosis Retroperitoneal Idiopática | Fibrosis retroperitoneal perianeurismática | Periaortitis crónicaItalia
-
Olympus Corporation of the AmericasGeisinger ClinicTerminado
-
Johns Hopkins UniversityGuerbetAún no reclutandoFibrosis miocárdicaEstados Unidos